EW · 10-Q · 2026Q2 · Full report

Geographic Market Commentary

Edwards Lifesciences Corp · 2026-08-04 · Importance 59 · Surprise 48 · No source text

All reported regions grew in the first six months of 2026, with sales increasing 12.3% in the United States to $1,941.1 million, 22.5% in Europe to $882.2 million, 5.6% in Japan to $187.0 million, and 18.8% in Rest of World to $379.3 million. Sales outside the United States rose 19.1% to $1,448.5 million. Product-specific growth was concentrated in the United States and Europe for PASCAL, EVOQUE, SAPIEN M3, and Surgical products, while SAPIEN 3 Ultra RESILIA growth also included Japan.

Key facts

• Europe net sales for the six months ended June 30, 2026 were $882.2 million, up $162.2 million (22.5%) from $720.0 million in 2025. source
• United States net sales for the three months ended June 30, 2026 were $1,003.5 million, up $113.8 million (12.8%) from $889.7 million in 2025. source
• United States net sales for the six months ended June 30, 2026 were $1,941.1 million, up $212.5 million (12.3%) from $1,728.6 million in 2025. source
• Europe net sales for the three months ended June 30, 2026 were $439.6 million, up $61.4 million (16.2%) from $378.2 million in 2025. source
• Net sales outside the United States for the six months ended June 30, 2026 were $1,448.5 million, up $232.2 million (19.1%) from $1,216.3 million in 2025. source
• Rest of World net sales for the three months ended June 30, 2026 were $201.5 million, up $32.5 million (19.3%) from $169.0 million in 2025. source
• Rest of World net sales for the six months ended June 30, 2026 were $379.3 million, up $60.1 million (18.8%) from $319.2 million in 2025. source
• Net sales outside the United States for the three months ended June 30, 2026 were $737.5 million, up $95.0 million (14.8%) from $642.5 million in 2025. source

Impact estimates